



State of Louisiana
Louisiana Department of Health
Bureau of Health Services Financing

MEMORANDUM

DATE: June 26, 2018

TO: All Louisiana Medicaid Prescribing Providers and Pharmacists

FROM: Jen Steele, Medicaid Director

SUBJECT: Louisiana Medicaid Fee for Service (FFS) Pharmacy Program Removal of Clinical Pre-Authorization Requirement for Sacubitril/Valsartan (Entresto®)

Effective July 1, 2018, the Louisiana Department of Health (LDH) FFS Pharmacy Program in conjunction with the Louisiana Medicaid Drug Utilization Review (LADUR) Program will remove the clinical pre-authorization requirement for sacubitril/valsartan (Entresto®).

Clinical Pre-Authorization Removal

Pharmacy claims for sacubitril/valsartan (Entresto®) will no longer require a Clinical Pre-Authorization. Prescribers will not have to complete the Pharmacy Clinical Pre-Authorization Form when prescribing sacubitril/valsartan (Entresto®).

If you have questions about the content of this memo, you may contact the FFS pharmacy help desk by phone at (800) 437-9101.

If you have questions about pharmacy claims billing, you may contact the Molina pharmacy help desk at (800) 648-0790.

Please forward this notice to other providers to assist with notification. Your continued cooperation and support of the Louisiana Medicaid Program efforts to coordinate care and improve health are greatly appreciated.

JS/MBW/GJS

c: Healthy Louisiana Plans
Melwyn B. Wendt
Molina